Nonagen's Oncuria granted FDA designation

2021 10 01 21 53 0927 Bladder Urinary 3 D 400

The U.S. Food and Drug Administration (FDA) has designated the Oncuria noninvasive bladder cancer test from Nonagen Bioscience as a breakthrough device.

The company said Oncuria is capable of predicting how a patient will respond to therapy. The multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.

Page 1 of 62
Next Page